Quality Segment
assay
≥95% (Gadolinium, elemental analysis)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
[O-]C(CN(CCN(C[C@H](CC1=CC=C(C=C1)OCC)N(CC([O-])=O)CC([O-])=O)CC([O-])=O)CC([O-])=O)=O.[Gd+3].[Na+].[Na+]
General description
Gadoxetate disodium is an amphipathic derivative of gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA). It is highly water soluble, hepatocyte-specific paramagnetic gadolinium-based MRI contrast agent. Structurally, it is an ionic, linear gadolinium-based agent with a lipophilic ethoxybenzyl (EOB) moiety covalently attached to gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA).
Application
Gadoxetate disodium may be used in liver and hepatobiliary imaging by enhancing the visualization of liver lesions, including tumors and metastases, and helping in assessing hepatobiliary disorders by providing detailed images of bile ducts and liver function.
Biochem/physiol Actions
Dual-excretion MRI contrast agent for liver-specific imaging, enhancing tumor detection, hepatic and biliary function assessment.
It is designed for enhanced imaging of liver structures and functions, with a unique dual excretion profile of 50% renal and 50% hepatic elimination. Its unique structure enables uptake by hepatocytes through the organic anion transporting polypeptide (OATP) and subsequent excretion into bile via multidrug resistance-associated proteins (MRPs). Gadoxetate uniquely distributes into vascular, extracellular, and hepatocellular spaces, allowing dual-function imaging to assess both liver function and biliary drainage while providing T1 relaxivity of 6.9 l mmol−1 s−1 at 1.5 T (in plasma). Clinically, this agent (intravenous bolus injection of 0.025 mmol/kg (0.1 mL/kg) body weight) is critical for detecting and characterizing liver tumors, evaluating hepatic function, and visualizing biliary system abnormalities, offering stable and targeted imaging with reduced gadolinium toxicity risk.
It is designed for enhanced imaging of liver structures and functions, with a unique dual excretion profile of 50% renal and 50% hepatic elimination. Its unique structure enables uptake by hepatocytes through the organic anion transporting polypeptide (OATP) and subsequent excretion into bile via multidrug resistance-associated proteins (MRPs). Gadoxetate uniquely distributes into vascular, extracellular, and hepatocellular spaces, allowing dual-function imaging to assess both liver function and biliary drainage while providing T1 relaxivity of 6.9 l mmol−1 s−1 at 1.5 T (in plasma). Clinically, this agent (intravenous bolus injection of 0.025 mmol/kg (0.1 mL/kg) body weight) is critical for detecting and characterizing liver tumors, evaluating hepatic function, and visualizing biliary system abnormalities, offering stable and targeted imaging with reduced gadolinium toxicity risk.
Disclaimer
Hygroscopic Store with desiccant
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable